Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis

Pharmacological Research

Volumn 63, Issue 3, 2011, Pages 241-248

  Maeda, Sayaka ^a   Matsui, Takanori ^a   Takeuchi, Masayoshi ^b   Yoshida, Yumiko ^a   Yamakawa, Ryoji ^a   Fukami, Kei ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; PEDF; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 4; FIBRONECTIN; HYDROETHIDINE; INSULIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CATTLE; CELLS, CULTURED; DIABETIC NEPHROPATHIES; EYE PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; NERVE GROWTH FACTORS; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; SERPINS;

EID: 79751527695     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.11.008     Document Type: Article

References (51)

1. S. Yamagishi, K. Fukami, S. Ueda, and S. Okuda Molecular mechanisms of diabetic nephropathy and its therapeutic intervention Curr Drug Targets 8 2007 952 959
2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
3. G. Remuzzi, A. Schieppati, and P. Ruggenenti Clinical practice. Nephropathy in patients with type 2 diabetes N Engl J Med 346 2002 1145 1151 (Pubitemid 34984606)
4. S. Yamagishi, and T. Matsui Advanced glycation end products, oxidative stress and diabetic nephropathy Oxid Med Cell Longev 3 2010 1018
5. J.L. Taft, C.J. Nolan, S.P. Yeung, T.D. Hewitson, and F.I. Martin Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria Diabetes 43 1994 1046 1051 (Pubitemid 24230711)
6. F.N. Ziyadeh, and S. Goldfarb The renal tubulointerstitium in diabetes mellitus Kidney Int 39 1991 464 475
7. H. Vlassara, and R. Bucala Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes Suppl 3 1996 S65 S66
8. M. Brownlee, A. Cerami, and A. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1998 1315 1321
9. S. Rahbar Novel inhibitors of glycation and AGE formation Cell Biochem Biophys 48 2007 147 157 (Pubitemid 47340881)
10. T.M. Wendt, N. Tanji, J. Guo, T.R. Kislinger, W. Qu, and Y. Lu RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am J Pathol 162 2003 1123 1137 (Pubitemid 36350658)
11. Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, and M. Takeuchi Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 2001 261 268 (Pubitemid 32656250)
12. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299 (Pubitemid 40872698)
13. S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications Expert Opin Invest Drugs 17 2008 983 996
14. S. Yamagishi, K. Nakamura, T. Matsui, Y. Noda, and T. Imaizumi Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication Curr Pharm Des 14 2008 487 495 (Pubitemid 351516853)
15. K. Fukami, S. Yamagishi, S. Ueda, and S. Okuda Role of AGEs in diabetic nephropathy Curr Pharm Des 14 2008 946 952 (Pubitemid 351753281)
16. J. Tombran-Tink, C.G. Chader, and L.V. Johnson PEDF: pigment epithelium-derived factor with potent neuronal differentiative activity Exp Eye Res 53 1991 411 414
17. J. Tombran-Tink, and C.J. Barnstable PEDF: a multifaceted neurotrophic factor Nat Rev Neurosci 4 2003 628 636 (Pubitemid 37280158)
18. D.W. Dawson, O.V. Volpert, P. Gillis, S.E. Crawford, H.J. Xu, and W. Benedict Pigment epithelium-derived factor: a potent inhibitor of angiogenesis Science 285 1999 245 248 (Pubitemid 29329995)
19. E.J. Duh, H.S. Yang, I. Suzuma, M. Miyagi, E. Youngman, and K. Mori Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth Invest Ophthalmol Vis Sci 43 2002 821 829 (Pubitemid 34184503)
20. Y. Inagaki, S. Yamagishi, T. Okamoto, M. Takeuchi, and S. Amano Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation Diabetologia 46 2003 284 287 (Pubitemid 36343893)
21. S. Yamagishi, S. Ueda, T. Matsui, K. Nakamura, T. Imaizumi, and M. Takeuchi Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties Protein Pept Lett 14 2007 832 835 (Pubitemid 47416409)
22. S. Sheikpranbabu, R. Haribalaganesh, K.J. Lee, and S. Gurunathan Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability Biochimie 92 2010 1040 1051
23. S.X. Zhang, J.J. Wang, G. Gao, C. Shao, R. Mott, and J.X. Ma Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor FASEB J 20 2006 323 325 (Pubitemid 46671158)
24. S. Yamagishi, T. Matsui, K. Takenaka, K. Nakamura, M. Takeuchi, and H. Inoue Pigment epithelium-derived factor prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs) Diabetes Metab Res Rev 25 2009 266 271
25. S. Yamagishi, T. Matsui, K. Nakamura, T. Yoshida, M. Takeuchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro Horm Metab Res 39 2007 233 235 (Pubitemid 46580625)
26. S. Yamagishi, T. Matsui, K. Nakamura, T. Yoshida, M. Takeuchi, and H. Inoue Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats Ophthalmic Res 39 2007 92 97 (Pubitemid 46909866)
27. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis Microvasc Res 72 2006 86 90 (Pubitemid 44118388)
28. S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, and Y. Jinnouchi Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220 (Pubitemid 44065796)
29. Y. Yoshida, S. Yamagishi, T. Matsui, Y. Jinnouchi, K. Fukami, and T. Imaizumi Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy Diabetes Metab Res Rev 25 2009 678 686
30. S. Yamagishi, T. Matsui, K. Nakamura, S. Ueda, Y. Noda, and T. Imaizumi Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications Curr Drug Targets 9 2008 1025 1029
31. S. Yamagishi, and T. Matsui Anti-atherothrombogenic properties of PEDF Curr Mol Med 10 2010 284 291
32. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J Biol Chem 277 2002 20309 20315 (Pubitemid 34967325)
33. S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, and Z. Makita Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties Biochem Biophys Res Commun 296 2002 877 882
34. K. Fukami, S. Ueda, S. Yamagishi, S. Kato, Y. Inagaki, and M. Takeuchi AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction Kidney Int 66 2004 2137 2147 (Pubitemid 41115277)
35. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells Kidney Int 63 2003 464 473 (Pubitemid 36126793)
36. S. Yamagishi, T. Matsui, H. Adachi, and M. Takeuchi Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population Pharmacol Res 61 2010 103 107
37. K. Nakamura, S. Yamagishi, T. Matsui, T. Yoshida, K. Takenaka, and Y. Jinnouchi Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation Am J Pathol 170 2007 2159 2170 (Pubitemid 47339287)
38. K. Takenaka, S. Yamagishi, T. Matsui, K. Nakamura, Y. Jinnouchi, and Y. Yoshida Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes Atherosclerosis 197 2008 25 33 (Pubitemid 351273269)
39. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression Pharmacol Res 61 2010 34 39
40. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation Biochem Biophys Res Commun 398 2010 326 330
41. G.H. Tesch MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy Am J Physiol Renal Physiol 294 2008 F697 701
42. M.E. Cooper Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy Diabetologia 44 2001 1957 1972 (Pubitemid 33124041)
43. T.C. Ho, S.L. Chen, Y.C. Yang, C.L. Liao, H.C. Cheng, and Y.P. Tsao PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells Cardiovasc Res 76 2007 213 223
44. T.C. Ho, Y.C. Yang, S.L. Chen, P.C. Kuo, H.K. Sytwu, and H.C. Cheng Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma Mol Immunol 45 2008 898 909
45. A.J. Jenkins, S.X. Zhang, K.G. Rowley, C.S. Karschimkus, C.L. Nelson, and J.S. Chung Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes Diabet Med 24 2007 1345 1351 (Pubitemid 350179436)
46. S. Yamagishi, H. Adachi, A. Abe, T. Yashiro, M. Enomoto, and K. Furuki Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome J Clin Endocrinol Metab 91 2006 2447 2450 (Pubitemid 43855041)
47. M. Takeuchi, Z. Makita, K. Yanagisawa, K. Kameda, and T. Koike Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients Mol Med 5 1999 393 405 (Pubitemid 29382313)
48. J. Miura, S. Yamagishi, Y. Uchigata, M. Takeuchi, H. Yamamoto, and Z. Makita Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes J Diabetes Compl 17 2003 16 21 (Pubitemid 36042787)
49. M.C. Thomas, C. Tikellis, P. Kantharidis, W.C. Burns, M.E. Cooper, and J.M. Forbes The role of advanced glycation in reduced organic cation transport associated with experimental diabetes J Pharmacol Exp Therap 311 2004 456 466 (Pubitemid 39391529)
50. J.J. Wang, S.X. Zhang, R. Mott, R.R. Knapp, W. Cao, and K. Lau Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities Diabetes 55 2006 1678 1685 (Pubitemid 44324120)
51. J.J. Wang, S.X. Zhang, R. Mott, Y. Chen, R.R. Knapp, and W. Cao Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy Am J Physiol Renal Physiol 294 2008 F1166 F1173